GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance ...
The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list. GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine (Nasdaq: HYPR), ...
President and CEO Maria Sainz reported first quarter revenue of $2.1 million from six system sales, noting this quarter marks the end of a period where the business relied mainly on U.S. hospital ...
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance ...
GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered ...
Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the Hyperfine Fourth Quarter 2024 ...
The MarketWatch News Department was not involved in the creation of this content. Hyperfine Delivers Quarterly Record Revenue of Approximately $5.3 Million in Q4 2025, Representing Transformative ...
Rafael O’Halloran, PhD, and Rob Fasciano, PhD, bring depth and breadth of experience in imaging and Medtech. Rob Fasciano, PhD, joined Hyperfine as Chief Regulatory and Quality Officer, bringing over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results